Dr Reddy's Adds To OTC Portfolio With Glenmark Deal
Acquires Anti-Allergy Brands In Russia, Ukraine, Kazakhstan And Uzbekistan
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
You may also be interested in...
Glenmark Builds US OTC Lineup In Wockhardt Deal
Glenmark acquires a portfolio of generic OTCs from Wockhardt marketed in US including famotidine 10- and 20-mgs; cetirizine 5- and 10-mgs; lansoprazole 15-mg delayed-release; and olopatadine hydrochloride 0.1% ophthalmic solution.
Glenmark Bolsters US OTC Portfolio With Wockhardt Products
Glenmark has moved to bolster its over-the-counter business in the US by acquiring a portfolio of approved generic OTC products from Wockhardt.
Acquisitions Are On Dr Reddy’s Menu
Dr Reddy’s indicates it is actively pursuing acquisitions, likely involving relatively smaller assets, across several key markets on the back of a “healthy” balance sheet. It is also progressing plans to position Russian COVID-19 vaccine Sputnik Light as a booster, which it believes could potentially be “part of life” hereon.